LTGO Latigo Biotherapeutics, Inc.

The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public offering, which raised over $85 billion in funding for Musk’s private space launch company, has accounted for the bulk of the first half’s IPO activity, but that is only part of the story. Even if you strip out SpaceX, the first half of this year saw new ‘traditional’ initial public offerings generate

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.

Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical data for its lead non opioid pain candidate LTG-001. See our latest analysis for Latigo Biotherapeutics. Since listing at US$18, Latigo Biotherapeutics’ share price has inched up to US$18.25, with a 1-day and year to date share price return of 1.39%, suggesting only early signs of momentum as...